LXRX Stock Summary and Trading Ideas (Lexicon Pharmaceuticals | NASDAQ:LXRX)

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Lexicon Pharmaceuticals trades on the NASDAQ stock market under the symbol LXRX.

As of November 9, 2026, LXRX stock price climbed to $1.82 with 2,434,692 million shares trading.

LXRX has a beta of 0.20, meaning it tends to be less sensitive to market movements. LXRX has a correlation of 0.00 to the broad based SPY ETF.

LXRX has a market cap of $809.82 million. This is considered a Small Cap stock.

Last quarter Lexicon Pharmaceuticals reported $11 million in Revenue and -$.03 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.02.

In the last 3 years, LXRX traded as high as $3.73 and as low as $.28.

The top ETF exchange traded funds that LXRX belongs to (by Net Assets): VTI, IWM, VXF, IWO, XPH.

LXRX has outperformed the market in the last year with a price return of +27.3% while the SPY ETF gained +13.4%. However, in the short term, LXRX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -22.9% vs -1.8% return in SPY. But in the last 2 weeks, LXRX shares have fared better than the market returning +28.2% compared to SPY -1.0%.

LXRX support price is $1.72 and resistance is $1.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LXRX shares will trade within this expected range on the day.